Paboriboune P. auteur aut IRD Vial Thomas auteur aut IRD Chassagne F. auteur aut IRD Sitbounlang P. auteur aut IRD Soundala S. auteur aut IRD Bertani Stéphane auteur aut IRD Sengmanothong D. auteur aut IRD Babin F. X. auteur aut IRD Steenkeste N. auteur aut IRD Deny P. auteur aut IRD Pineau P. auteur aut IRD Deharo Eric auteur aut IRD text journalArticle eng text/pdf reformatted digital access Objective. Lao PDR is one of the most highly endemic countries for hepatitis B in Asia and the second country for liver cancer incidence. Therefore, the follow-up of infected individuals through predictive serological markers is of utmost importance to monitor the progression of the pathology and take the decision on treatment. Methods. A retrospective-descriptive cohort study was conducted on 3,857 HBV-infected patients. Information about infection status (viral load, VL), liver function (aminotransferases), and treatments was recorded. Results. M/F sex ratio was 1.77 for a median age of 37. Patients under 37 displayed higher VL than older ones and men had higher VL than women. Initial VL ranged from <50 IU/mL to 2.5 10(13) IU/mL. Median aminotransferase values were 45.5 U/L for ALAT and 44 U/L for ASAT, ranging from <8 to >2,000 U/L. Men had higher aminotransferase than women. Globally 20% of patients received treatment (mainly immunostimulant and reverse-transcriptase inhibitors); 11% had high levels of VL and liver enzymes, but only 2% of them were treated. Conclusion. Public health decisions should be taken urgently to rationalise vaccination and provide fair access to early diagnosis and treatment; otherwise the burden of HBV-associated diseases will be overwhelming for Laos in the near future. specialized LAOS 050 052 art. ID 9462475 [11 ] 2018 2090-3448 https://www.documentation.ird.fr/hor/fdi:010072740 10.1155/2018/9462475 2090-3448 [F B010072740] https://www.documentation.ird.fr/hor/fdi:010072740 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers18-05/010072740.pdf IRD - Base Horizon / Pleins textes 2018-06-01 2024-08-12 fdi:010072740 fre